Showing 2571-2580 of 3315 results for "".
- Bausch + Lomb and Glaucoma Research Foundation Launch 'Faces of Glaucoma' Campaignhttps://modernod.com/news/bausch-lomb-and-glaucoma-research-foundation-launch-faces-of-glaucoma-campaign/2482039/Bausch + Lomb and the Glaucoma Research Foundation (GRF) have launched “Faces of Glaucoma,” a campaign that will highlight diverse patient stories and raise awareness of the second leading cause of blindness worldwide. The campaign will run through January, which is Glaucoma
- Aetna Rolls Back Prior Authorization for Cataract Surgeries for Medicare Advantage Beneficiaries in Georgiahttps://modernod.com/news/aetna-rolls-back-prior-authorization-for-cataract-surgeries-for-medicare-advantage-beneficiaries-in-georgia-1/2482030/After 2 years of advocacy from the ophthalmology community, Aetna confirmed in a letter to the American Academy of Ophthalmology that it will no longer require preapproval for cataract surgeries for Medicare Advantage beneficiaries in Georgia, starting Jan.1. Last year, the insurer rolled back th
- ECM Therapeutics Collaborates with the University of Pittsburgh Vision Institute to Advance Technology for Optic Nerve Repairhttps://modernod.com/news/ecm-therapeutics-collaborates-with-the-university-of-pittsburgh-vision-institute-to-advance-technology-for-optic-nerve-repair/2482023/ECM Therapeutics announced a collaboration with the Louis J. Fox Center for Vision Restoration at the UPMC and Pitt Vision Institute to leverage a platform technology called Matrix Bound Nanovesicles (MBV) that has recently shown potential to promote restoration of injure
- New Report Calls for a National Eye Care Plan for England to Address Surging Patient Demandhttps://modernod.com/news/new-report-calls-for-a-national-eye-care-plan-for-england-to-address-surging-patient-demand/2482003/As part of Westminster Eye Health Day, stakeholders and experts from across the eye health sector have launched a new report laying out action required to improve eye care for patients in England. The initiative is led by "The Eyes Have It," a partnership of Macular Society, Fight
- Ophtec Launches Precizon Go IOL for Enhanced Intermediate Visionhttps://modernod.com/news/ophtec-launches-precizon-go-iol-for-enhanced-intermediate-vision/2482002/Ophtec announced the launch of the Precizon Go, a hybrid acrylic IOL designed to provide distance and enhanced intermediate vision. The lens is designed to offer natural vision at far and enhanced intermediate vision, without compromising the quality of vision at any
- New "Eye Chart" App Designed to Address Common Challenges in Near Vision Testinghttps://modernod.com/news/new-eye-chart-app-designed-to-address-common-challenges-in-near-vision-testing/2481995/A new app aims to address common challenges encountered in near vision testing. The "Eye Chart" app, which was developed by Michael Ullman, MD, a cornea specialist at Ullman Eye Consultants in Pensacola, Florida, leverages the iPhone's TrueDepth camera to me
- Atsena Therapeutics Announces 12-Month Safety and Efficacy Data from Phase 1/2 Trial of ATSN-101 in Patients with LCA1https://modernod.com/news/atsena-therapeutics-announces-12-month-safety-and-efficacy-data-from-phase-12-trial-of-atsn-101-in-patients-with-lca1/2481991/Atsena Therapeutics announced positive 12-month safety and efficacy data from the ongoing phase 1/2 trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). At 12 months post-treatment, ATSN-101 ha
- Mass Eye and Ear Researchers Develop Potential Glaucoma Treatment Strategy to Guide Stem Cells to the Retinahttps://modernod.com/news/mass-eye-and-ear-researchers-develop-potential-glaucoma-treatment-strategy-to-guide-stem-cells-to-the-retina/2481977/A multidisciplinary team led by researchers at the Schepens Eye Research Institute of Mass Eye and Ear has identified a promising new strategy for glaucoma cell replacement therapy. In a new study, researchers changed the microenvironment in the eye in a way that enabled them to take st
- Atsena Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Gene Therapy for LCA1https://modernod.com/news/atsena-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-gene-therapy-for-lca1/2481966/Atsena Therapeutics announced the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ATSN-101, the company’s lead investigational gene therapy for patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). RMAT desi
- Research Unveils Potential Breakthrough in Diabetic Retinopathy Treatmenthttps://modernod.com/news/research-unveils-potential-breakthrough-in-diabetic-retinopathy-treatment/2481962/Researchers from Washington University in St. Louis have discovered a potential new treatment approach to diabetic retinopathy. Diabetic retinopathy’s enigma unfolds with the role of microglia, immune cells resident in the retina. When confronted with high blood glucose levels, th